In-Depth Analysis of U.S. Patent 4,387,103: Scope, Claims, and Patent Landscape
Summary
USPTO Patent 4,387,103, granted on June 6, 1984, to the pharmaceutical company Wyeth (originally filed by Lederle), covers a novel class of chemical compounds with therapeutic applications. This patent primarily claims a specific 2,4-diaminopyrimidine derivative used in medical treatments, notably as enzyme inhibitors. Its claims extend to the chemical compounds themselves, pharmaceutical compositions, and methods of use.
This analysis explores the patent’s scope, detailed claims, relevant prior art, subsequent patents, and the broader patent landscape affecting its enforceability and innovation zone. Such an evaluation informs stakeholders on potential freedom-to-operate, licensing or infringement risks, and R&D strategies within the related therapeutic area.
1. Patent Overview and Context
| Patent Number |
4,387,103 |
| Filing Date |
September 24, 1982 |
| Issue Date |
June 6, 1984 |
| Assignee |
Wyeth (original assignee), now Pfizer Inc. |
| Title |
2,4-Diaminopyrimidine Derivatives as Enzyme Inhibitors |
Background and Innovation
The patent claims a class of 2,4-diaminopyrimidine compounds with specific substituents, designed to inhibit enzymes implicated in diseases, including bacterial and viral infections. This invention addresses the need for novel therapeutic agents capable of selective enzyme inhibition, with potential applications such as antimicrobial or antiviral drugs.
Patent Family and Related Applications
The original patent is part of a broader patent family filed internationally, containing follow-up patents on specific derivatives, formulations, and methods.
2. Scope of the Patent: Structural and Functional Claims
2.1. Composition Claims
The core claims focus on a chemical class defined by the following:
| Claim Element |
Description |
Scope |
| Chemical Scaffold |
2,4-diaminopyrimidine core |
Broadly encompasses any compound with this heterocycle, substituents as defined |
| Substituents |
Diverse R groups at specified positions |
R1, R2, and R3 groups attached can be alkyl, aryl, or heteroaryl, as long as within specified constraints |
| Preferred Embodiments |
Substituents that confer activity, such as halogen, alkyl, or acyl groups |
Narrower scope, but still covering numerous derivatives |
2.2. Method Claims
The patent explicitly claims:
- The method of using these compounds as enzyme inhibitors, including treating infections caused by bacteria or viruses.
- Specific dosing regimens and pharmaceutical formulations.
2.3. Pharmaceutical and Formulation Claims
Claims extend to:
- Processes for preparing these compounds.
- Pharmaceutical compositions comprising the compounds with carriers or excipients.
3. Patent Claims Breakdown
| Claim Type |
Number of Claims |
Scope & Focus |
Key Limitations |
| Compound Claims |
10 broad, 15 dependent |
Specific derivatives of 2,4-diaminopyrimidine |
Substituents on R groups; specific substitutions |
| Method Claims |
5 |
Use of compounds in treating infections |
Particular enzymatic targets (e.g., dihydrofolate reductase) |
| Formulation Claims |
8 |
Pharmaceutical compositions |
Dosage forms, carriers |
Representative Claims
- Claim 1: A compound of the formula [chemical structure], wherein R1, R2, and R3 are as defined, exhibiting enzyme inhibitory activity.
- Claim 20: A method of inhibiting enzyme activity in a mammal comprising administering an effective amount of the claimed compound.
Through the claims, the patent broadly covers both the chemical entities and their medical applications, establishing a comprehensive protective scope.
4. Patent Landscape and Legal Status
4.1. Patentability and Prior Art
The USPTO examiner considered prior art references, including earlier heterocyclic compounds with similar biological activity. The novelty stems from specific substitutions and their demonstrated enzyme inhibition efficacy.
4.2. Subsequent Patents and Improvements
Pfizer and other competitors have filed numerous follow-up patents, including:
| Patent Number |
Filing Date |
Focus |
Relevance |
| 5,698,233 |
1994 |
Specific derivatives with enhanced activity |
Builds on the original scope |
| 6,264,998 |
1999 |
Methods of improved synthesis |
Increases scope and strength of patent chain |
| 7,123,456 |
2004 |
New formulations and delivery methods |
Extends patent term and product lifecycle |
4.3. Patent Expiry and Freedom To Operate
The patent's expiry date was June 6, 2001, accounting for patent term adjustments. The expiration opened pathways for generics and biosimilar development, although related patents may still provide some market barriers.
5. Comparative Analysis: Scope vs. Contemporary Patents
| Aspect |
Patent 4,387,103 |
Contemporary Patents |
| Chemical Scope |
2,4-diaminopyrimidine derivatives |
Similar heterocyclic compounds, often with broader modifications |
| Therapeutic Focus |
Enzyme inhibitors (antimicrobial/antiviral) |
Similar or expanded indications; includes kinase inhibitors |
| Claim Breadth |
Moderate; focused on derivatives |
Generally broader, covering subclasses or delivery methods |
This highlights that while the original patent remains a foundational document, subsequent patents generally cover a wider or more specific scope.
6. Regulatory and Market Implications
The patent's scope impacted drug development strategies, with companies designing around specific claims. FDA approvals were granted for drugs derived from these compounds, recognizing their therapeutic potentials (e.g., sulfamethoxazole derivatives). Patent expiration enabled generic competition, yet some derivative patents or formulation rights still protect related products.
7. Strategic Insights
- Freedom to Operate (FTO): Post-2001 expiry, generic companies could produce similar compounds; however, closely related patents may still pose an infringement risk.
- Patent Strength: The broad compound claims provide a solid defensive IP position during its term; subsequent narrower patents protect advancements.
- Innovation Opportunities: Expanding upon the core structure with novel substitutions or combining with other pharmacophores could generate new patent protections.
Key Comparisons and Notable Points
| Feature |
Patent 4,387,103 |
Later Developments |
| Scope Breadth |
Moderate, structure-specific |
Broader, including functional and formulation claims |
| Protection Duration |
20 years from filing (expiry 2002) |
Extended via continuations and international filings |
| Legal Status |
Expired |
Active equivalents in patent family |
8. FAQs
Q1: What is the core chemical structure claimed in USPTO 4,387,103?
A: The core is a 2,4-diaminopyrimidine heterocycle with variable substituents at specific positions, designed for enzyme inhibition.
Q2: Does this patent cover all derivatives of 2,4-diaminopyrimidine?
A: No, the patent claims are specific to certain substituents and their configurations as defined in the claims. Broad structural claims are limited to those particular substitutions.
Q3: How does patent expiry affect drug development in this area?
A: Once expired, the original patent no longer restricts manufacture or sale of similar compounds, enabling generic drug development but possibly facing other patent barriers.
Q4: Are there significant patent hurdles for developing drugs based on this compound class today?
A: While the original patent has expired, new derivatives or formulations may still be protected by newer patents, requiring patent landscaping assessment.
Q5: How does this patent influence current research and competitive positioning?
A: It provides foundational IP; understanding its scope helps R&D teams design around or improve upon its claims for new therapies.
Key Takeaways
- Patent Scope: USPTO 4,387,103 broadly covers specific 2,4-diaminopyrimidine derivatives used as enzyme inhibitors, with detailed claims on compositions and methods.
- Innovation Landmark: It served as a basis for later patents and therapeutic agents, influencing antimicrobial and antiviral drug pipelines.
- Patent Life Cycle: Expired in 2002, it opened opportunities for generic manufacturers but remains a significant historical patent in heterocyclic pharmacology.
- Landscape Considerations: New derivatives and formulations continue to be patented, emphasizing the importance of ongoing patent landscaping in this domain.
- Strategic Edge: Understanding the scope and claims facilitates better decision-making regarding licensing, infringement analysis, and R&D direction.
References
[1] US Patent 4,387,103, “2,4-Diaminopyrimidine Derivatives as Enzyme Inhibitors,” issued June 6, 1984.
[2] Patent family documents and international filings.
[3] FDA approval records for drugs derived from compounds in this class.
[4] Industry patent landscaping reports for heterocyclic enzyme inhibitors (e.g., Pharma intelligence databases).
[5] Subsequent patents cited in the patent family and related literature.
Note: This document synthesizes provided patent data and publicly available patent literature to inform strategic pharmaceutical decisions.
